Shopping cart ITEMS
 modern scholarly publishers in the finest tradition
Login Register
Home
Books
Journals
References
A-Z Index
Author Index
For Our Authors
User Area
Shopping Cart
Contact
Electronic Data Center

Journal of Environmental Pathology, Toxicology and Oncology

 

ISSN for PRINT: 0731-8898

Institutional price:

$672.00

Issues per year:

4

For Online Access

Best Paper Award Selection - Editorial Board Site

Add subscription to shopping cart

2006, Volume25

Issue 3

  82 pages  

   

click 'Save as...' here to save XML metadata

Issue price - $172.00  

Add to shopping cart

  • Carcinogenicity and Chronic Toxicity of Para-Chloronitrobenzene in Rats and Mice by Two-Year Feeding
  • Michiharu Matsumoto
    Japan Bioassay Research Center, Japan Industrial Safety and Health Association, Hirasawa, Hadano, Kanagawa, Japan

    Shigetoshi Aiso
    Japan Bioassay Research Center, Japan Industrial Safety and Health Association, Hirasawa, Hadano, Kanagawa, Japan

    Hideki Senoh
    Japan Bioassay Research Center, Japan Industrial Safety and Health Association, Hirasawa, Hadano, Kanagawa, Japan

    Kazunori Yamazaki
    Japan Bioassay Research Center, Japan Industrial Safety and Health Association, Hirasawa, Hadano, Kanagawa, Japan

    Heihachiro Arito
    Japan Bioassay Research Center, Japan Industrial Safety and Health Association, Hirasawa, Hadano, Kanagawa, Japan

    Kasuke Nagano
    Japan Bioassay Research Center, Japan Industrial Safety and Health Association, Hirasawa, Hadano, Kanagawa, Japan

    Seigo Yamamoto
    Japan Bioassay Research Center, Japan Industrial Safety and Health Association, Hirasawa, Hadano, Kanagawa, Japan

    Taijiro Matsushima, Ph.D.
    Japan Bioassay Research Center, Japan Industrial Safety and Health Association, Hirasawa, Hadano, Kanagawa, Japan


    ABSTRACT

    Carcinogenicity and chronic toxicity of para-chloronitrobenzene (p-CNB) were examined by feeding diets containing p-CNB to rats and mice of both sexes for two years. The dietary concentration of p-CNB was 0 (control), 40, 200, or 1000 ppm (w/w) for rats and 0, 125, 500, or 2000 ppm for mice. Survival rates of the high-dosed male rats and male mice were significantly decreased compared with those of the respective controls, and this was attributed to the increased number of cancer deaths. Therefore, the high-dose levels were considered not to exceed the maximum tolerated dose. Significant decreases in red blood cell counts and hematocrit value and an increase in mean corpuscular volume were noted in the p-CNB-fed rats and mice. Nonneoplastic splenic lesions were characterized by capsule hyperplasia, fibrosis, fatty metamorphosis, and increased extramedullary hematopoiesis in rats, and congestion, increased extramedullary hematopoiesis, hemosiderin deposition, and ossification in mice. Incidences of fibromas, fibrosarcomas, osteosarcomas, sarcomas (NOS), and hemangiosarcomas in males and fibrosarcomas in females were significantly increased in the spleen of high-dosed rats. The most frequently observed splenic tumor was fibrosarcomas, followed by fibromas. The tumor incidences were increased in a dose-related manner and were more prevalent in males than in females. The malignant tumors metastasized mainly to the liver, peritoneum, and pancreas. Adrena/medullary hyperplasia and pheochromocytomas were significantly increased in the p-CNB-fed females. No tumor was induced in any of the p-CNB-fed mice of either sex except hepatic hemangiosarcomas in the 2000 ppm-fed females. Causative factors of p-CNB-induced carcinogenicity and chronic toxicity are discussed in light of the subchronic and chronic hematotoxicity reported in our present and previous studies and in the literature.

    Download article, 571-584 pages

    Article price - $35.00  

    Add to shopping cart

    << Previous article   Next article >>

    Designed by offsiteteam Designed by offsiteteam Designed by offsiteteam
    Begell House Inc.
    50 Cross Highway,
    Redding, CT 06896
    TEL (203) 938 1300
    FAX (203) 938 1304
    orders@begellhouse.com